Migraine
Migraine is arguably the most common neurological condition, affecting up to 80% of adults at some time in their lives.
| Condition(s) | Type of Drug | Phase | Add-On | Placebo | Duration | Open-Label Extension |
|---|---|---|---|---|---|---|
| Pediatric episodic migraine, under 15 days per month | Approved Emgality monthly injection | III | Yes | 50% | 3 months | 3 months |
| Pediatric chronic migraine, 15 or more days per month | Approved Emgality monthly injection | III | Yes | 50% | 3 months | 3 months |
| Pediatric episodic migraine abortive therapy | Approved Reyvow oral drug | III | Yes | 50% | 24 weeks | |
| Pediatric chronic migraine abortive therapy | Approved Revyow oral drug | III | Yes | 50% for 3 months, then 0% for 9 months | 12 months | |
| Adult episodic migraine preventive | IV PACAP inhibitor | III | Yes | 50% | 24 weeks |
Response Form
If you or a loved one is interested in participating in one of our trials, please contact us at (855) 829-8899 or use the form below. One of our skilled Clinical Research Coordinators will contact you as soon as possible. Thank you for your interest in our research!
| Joshua A. Tobin, MD, Director of Migraine Research |
| Stephen S. Flitman, MD, Medical Director |
